Skip to main content

John Anson, Michael Kallelis, Mike Wandell, James Douglas, Ian Campbell, David Lockhart, CombiMatrix, Agilent Technologies

Premium

People in the News

Oxford Gene Technology appointed John Anson as research and development director, the company said last week.

Anson spent 16 years at Amersham Biosciences/GE Healthcare where he held various executive positions, including head of product development. He holds a PhD in bacterial genetics from Cranfield University and a BSc in microbiology from the University of Kent.


Exiqon said last week that Michael Kallelis will head the company's US operations in Boston as president and general manager.

Before joining Exiqon, Kallelis was vice-president at Archemix and executive vice-president and general manager at Avecia Biotechnology. He co-founded Boston BioSystems, which was acquired by Avecia in 1999.


Epigenomics has named Mike Wandell as senior vice-president for clinical, regulatory and quality affairs, and James Douglas as senior vice-president of marketing and sales, the company said last week.

Both Wandell and Douglas will be based in Seattle, Wash.

Wandell previously served as director of business development and regulatory affairs with Genetic Systems, chief scientific officer at Home Access Health, and vice-president of clinical and regulatory affairs with LipoSonix.

Douglas spent 18 years in biotechnology companies including Gen-Probe, Sanofi Diagnostics Pasteur, Centocor, Abbott Diagnostics, and Biosite.


Akubio has appointed Ian Campbell to the position of business development director, the British biosensor company said this week.

Campbell served previously as a business development consultant with the Automation Partnership. Prior to Automation Partnership, Campbell worked in business development at Corning Microarray Technology. He also played a commercial role at Biacore.


Amicus Therapeutics has named David Lockhart as its chief scientific officer, the biopharmaceutical company said this week.

Lockhart most recently served as president and chief scientific officer of Ambit Biosciences in San Diego. He previously served Affymetrix as vice president of genomics research.

Lockhart holds a PhD in chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute at the Massachusetts Institute of Technology.

 

New Product Watch

CombiMatrix last week announced a new line of Species-Specific MicroRNA arrays on its CustomArray platform.

The company is offering arrays for human, mouse, rat, C. elegans, Drosophila, Arabidopsis, and maize, priced at $99 per array. A compendium array, featuring all known microRNAs, is also being sold, CombiMatrix said.


Agilent Technologies this week launched its dual-mode, one-color/two-color microarray platform, which it claims can be used for either one-color or two-color experiments to match researchers' requirements.

The dual-mode microarrays use Agilent's 60-mer probes printed through its inkjet in situ microarray manufacturing process. In addition, Agilent said data created using the dual-mode arrays has recently been submitted to the US Food and Drug Administration's Microarray Quality Control project.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.